Dong-A turns its eyes to Chinese market

Published: 2003-03-04 06:56:00

Updated: 2003-03-04 06:56:00

Dong-A says it newly established Wuhan Donghe Pharma, a joint venture firm, with Donghe Corporation under the same 50:50 equity ratio of investment amounting to a total $250,000 in an effort to market Dong-A's own drugs including Panpyrin, etc. in the Chinese market.

According to Dong-A Pharm,...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK